A Practical Guide for Medical Device Manufacturers
Regulatory compliance for dental products has become far more complex over the past decade. What was once a relatively straightforward pathway is now a demanding, lifecycle‑driven process that requires robust technical and clinical evidence, structured post‑market surveillance, and ongoing regulatory oversight.
For manufacturers bringing dental products to market, especially under the EU Medical Device Regulation (MDR), compliance is no longer a single milestone. It is a continuous obligation that influences product design, technical documentation, clinical evidence, and post‑market performance activities throughout the entire lifecycle.
From our experience as a consulting company supporting medical device manufacturers, dental products often lie at the crossroads of material science, clinical performance, and stringent regulatory requirements. This combination makes regulatory compliance both critical and increasingly challenging for manufacturers aiming to achieve and maintain market access.
What Regulatory Compliance Means for Dental Products
Dental products as dental medical devices
Many dental products are legally classified as medical devices, even when they are commonly perceived as materials or components. Items such as dental alloys, implantable components, restorative materials, and certain software‑driven solutions fall under medical device regulations when intended for a medical purpose.
This classification carries specific regulatory obligations for manufacturers, whether the product is used directly by clinicians or indirectly through dental laboratories.
Responsibility across the dental product lifecycle
Regulatory compliance extends far beyond initial approval. As is the case for other medical device manufacturers, dental manufacturers remain responsible for:
- Defining and maintaining the intended purpose
- Ensuring ongoing safety and performance
- Monitoring post-market data
- Updating documentation as evidence evolves
Importantly, many compliance failures do not arise from missing documents, but from misalignments and inconsistencies across lifecycle activities. Maintaining clear linkage between purpose, evidence, and post-market insights is essential for demonstrating a coherent and compliant lifecycle strategy. When these key elements stay aligned, manufacturers strengthen regulatory trust, reduce risk, and support smoother long-term market access. This principle applies equally to dental medical devices and to all other medical devices, as it is transversal across the sector.
Why dental products face increased scrutiny
Dental devices frequently involve:
- Implantable or long-term contact materials
- Complex alloy compositions
- Large legacy portfolios originally certified under previous regulations
These features introduce specific regulatory expectations. Implantable and long-term contact materials require robust biocompatibility assessments and long-term safety evaluations. Additionally, complex alloys may require chemical and toxicological evaluations to ensure that all constituent materials meet biological safety standards. Finally, legacy products, previously certified under less stringent requirements, must now be re-evaluated using updated evidence to demonstrate continued safety and performance under current frameworks.
Together, these factors increase expectations for clinical evidence, biological safety, and post-market surveillance, leading to closer regulatory scrutiny and more rigorous conformity assessment processes.
Which Regulations Apply to Dental Medical Devices?
European Union: EU MDR
In the European Union (EU), medical devices are governed by Regulation (EU) 2017/745 (MDR). Compared to the former Medical Device Directives (MDD/AIMDD), MDR introduces:
- Stronger clinical evidence requirements
- Enhanced post-market surveillance obligations
- Increased scrutiny from Notified Bodies
- Clearer expectations for technical documentation consistency
Manufacturers of dental devices are therefore required to fulfil these additional requirements to ensure the device is compliant with EU market requirements.
United Kingdom: UK MDR and UKCA Marking
In the United Kingdom (UK), medical devices are regulated under the UK Medical Devices Regulations 2002 (as amended), with oversight by the Medicines and Healthcare products Regulatory Agency (MHRA). Following Brexit, the UK has established an independent regulatory framework, while maintaining transitional recognition of CE marking in Great Britain.
Compared with the EU MDR, the UK framework introduces a parallel but distinct pathway, characterized by:
- The progressive transition from CE marking to UKCA marking for Great Britain
- UK-specific registration requirements with the MHRA
- Potential divergence in timelines, conformity assessment routes, and regulatory interactions
- The need to monitor evolving UK legislation as the framework continues to develop
Manufacturers of dental devices must therefore define a clear UK regulatory strategy, ensuring that UKCA requirements (and transitional CE provisions, where applicable) are properly addressed, while maintaining alignment with EU documentation and lifecycle activities to the extent possible.
United States of America: FDA
The United States can also be an attractive market for dental devices. For manufacturers wishing to operate beyond Europe, dental product compliance must align with FDA expectations or other international frameworks. While this article focuses on EU MDR, a global regulatory strategy should aim for evidence reuse and lifecycle consistency across jurisdictions.
Maintaining a broad perspective on regulatory expectations in different markets enables more efficient submissions at various time points, minimizing duplicated effort and ensuring smoother pathways to global market access.
Regulatory Classification of Dental Products in EU
How to determine classification
Under MDR, dental devices are classified based on:
- Intended purpose
- Duration of contact
- Invasiveness
- Implantable status
Many dental materials and alloys are classified as higher risk than expected, particularly for implantable or long-term applications. Understanding these rules early helps ensure accurate classification.
Why classification drives EU regulatory strategy
Classification decisions affect:
- Conformity assessment routes
- Clinical evidence depth
- Post-market obligations
- Notified Body involvement
Misclassification early in development often leads to costly rework later, particularly once technical documentation has been developed or regulatory submissions have begun. Manufacturers must also avoid making changes to the product or its intended purpose after commercialization that could alter its classification and trigger additional regulatory requirements. Establishing the correct classification from the outset and maintaining alignment throughout the lifecycle are essential to a smooth, predictable regulatory pathway.
Learning from Real-World MDR Transitions in Dental Products
Across MDR transition projects involving complex dental portfolios, one lesson consistently emerges: regulatory compliance succeeds when evidence, processes, and documentation are aligned from end to end.
Large dental product families require structured execution, clear ownership, and realistic timelines. Compliance is less about individual documents and more about how well the regulatory system functions as a whole.
If you want to see how these principles apply in practice, you can read our full case study on an MDR transition for dental products.
Core Regulatory Requirements for MDR Compliance of Dental Products
Technical documentation and conformity assessment
Regulatory compliance for dental products starts with technical documentation that clearly and consistently supports the device’s safety and performance. Under MDR, this documentation is reviewed as a single, connected system rather than as separate files.
Manufacturers must demonstrate that the device is well defined, risks are properly controlled, and clinical and biological evidence support the intended use. In practice, regulatory findings often arise not because documents are missing, but because different parts of the technical file are not fully aligned.
Clinical evaluation
Clinical evaluation must show that the dental device performs as intended and remains safe throughout its lifecycle. This assessment is typically based on a combination of clinical data, relevant scientific literature, and post-market evidence where available.
For dental devices, regulators closely scrutinize whether clinical claims align with the intended purpose and the conclusions from risk management activities. Any inconsistency between these elements is one of the most frequent causes of Notified Body questions during technical documentation review. Ensuring consistency across intended purpose, clinical evidence and risk conclusions is essential for a smooth clinical evaluation process.
Biological evaluation and material safety
Biological evaluation is particularly important for dental materials that come into prolonged or permanent contact with the body. Manufacturers are expected to follow a structured, risk-based approach that justifies testing, addresses worst-case configurations, and integrates toxicological considerations where relevant.
Weak biological rationales or conclusions that are not reflected in risk management and labelling are frequent sources of non-conformities. A coherent and well documented evaluation is therefore essential to demonstrate material safety and regulatory compliance.
Risk management and traceability
Risk management under MDR is a continuous process, not a one-time activity. Regulators increasingly expect clear traceability between identified hazards, risk control measures, supporting clinical and biological evidence, and the information provided to users.
Consistency over time is critical. Risk management conclusions must remain aligned with clinical evaluation updates and post-market data as new information becomes available.
Labelling and instructions for use (IFUs)
Labelling and IFUs must accurately reflect the device’s intended use, residual risks, contraindications, and safety-related information. Inconsistencies between labelling and technical documentation are a common reason for regulatory findings.
Under MDR, labelling is assessed as a direct extension of the manufacturer’s risk and clinical conclusions, not as a standalone deliverable. Correct and well-structure labelling and IFU is particularly important because it is often the only information the end user will directly interact with. Clear and accurate instructions reduce the likelihood of misuse, improve clinical outcomes, and contribute to patient safety.
Post-Market Obligations for Dental Medical Devices under MDR
Post-Market Surveillance (PMS)
PMS systems must actively collect and analyse real-world data to ensure devices continue to perform safely and effectively once in clinical use. This includes:
- Complaint handling
- Trend analysis and early detection of potential risks
- Vigilance reporting
- Periodic safety updates
For dental devices, many of which are used repeatedly and placed in the oral cavity for long durations, post-market provides essential insight into performance across different clinical environments and users.
PMCF and PSUR
Depending on classification and associated risk, manufacturers may be required to implement:
- Post-Market Clinical Follow-up (PMCF)
- Periodic Safety Update Reports (PSUR)
PMCF is especially relevant in dentistry, where varied patient populations and technique-sensitive procedures can impact long-term outcomes. PSURs ensure that these insights are systemically gathered, assessed and fed back into the technical documentation.
Why Post-Market Data matters beyond compliance
Post-market activities are not simply regulatory obligations. They play a strategic and clinical role, helping manufacturers:
- Identify how products perform in diverse real-world dental practices
- Detect early signs of wear, degradation or unexpected biological responses
- Refine IFUs, contraindications or warnings based on real-use scenarios
- Support claims of durability, reliability, and biocompatibility with ongoing evidence
- Strengthen competitiveness by demonstrating proven, long-term performance
Post-market data is therefore not optional and is central to demonstrating ongoing compliance and to maintaining clinical confidence, improving product quality, and supporting future innovation.
Common MDR Regulatory Compliance Challenges for Dental Products
Legacy devices and MDR transitions
Many dental products on the market today were originally certified decades ago, under earlier regulatory frameworks. Although the MDR entered into full application in 2021, transition periods extend to 2028 (depending on device classification). For legacy devices, a structured gap assessment is essential to identify missing requirements or outdated evidence. Transitioning these products to MDR often reveals gaps in:
- Clinical evidence
- PMS systems
- Biological evaluation rationale
- Consistency and traceability across technical documentation
Because many legacy dental products were introduced before modern evidence expectations existed, manufacturers often face significant redevelopment of foundational documentation. Early planning is critical to avoid bottlenecks as MDR deadlines approach.
Portfolio-level complexity
Manufacturers of dental devices typically manage large and diverse portfolios, often with hundreds of variants differing in materials, shade, formulation, packaging or indications. This scale creates a substantial challenge when aligning all products with MDR requirements. To maintain control and ensure all technical documentation is complete and updated, manufacturers require:
- Structured regulatory frameworks that define consistent expectations
- Harmonised documentation strategies that minimise duplication of work across similar devices
- Scalable and robust post-market systems capable of handling extensive product families
Without a systematic, portfolio-level approach, MDR compliance efforts can become fragmented and inefficient. In many cases, non-conformities arise from a lack of strategic coordination across product lines.
Notified Body expectations
Notified Bodies evaluate more than simply the existence of documentation. They assess how effectively manufacturers control their devices throughout the entire lifecycle. Depending on the classification of the dental device, the involvement of a Notified Body can be required for its initial certification, ongoing surveillance, and continued market access. As such, manufacturers must therefore be prepared for both announced and unannounced audits. Maintaining an “audit-ready” state requires:
- Evidence coherence, ensuring clinical, biological, risk and labelling conclusions fully align
- Lifecycle thinking, with post-market data and risk updates continuously feeding into the technical file
- Demonstrated control, not just document availability, meaning systems, processes and records clearly show that compliance is maintained
Ultimately, maintaining this level of operational readiness demonstrates that the manufacturer is in continuous control of product quality and regulatory compliance. This proactive posture not only supports smoother audits but also builds long-term confidence with Notified Bodies. It signals that the manufacturer can reliably uphold MDR expectations throughout the entire lifecycle, ensuring stable and sustained market access.
The Role of MDx in Dental Product Regulatory Compliance
MDx supporting Manufacturers
Manufacturers typically engage MDx when:
- Internal teams need execution support
- Portfolios are large or complex
- Timelines are constrained
- Notified Body interactions intensify
MDx provides specialized regulatory expertise and operational capacity, helping manufacturers manage high workloads, accelerate progress, and confidently navigate regulatory expectations.
Execution vs. advisory support
For many manufacturers, advisory guidance alone is not sufficient to move projects forward efficiently. Effective MDx support combines strategic insight with hands-on execution, ensuring:
- Development of compliant and high-quality documentation
- Evidence generation and alignment across clinical, regulatory and quality domains
- Practical experience navigating audits and regulatory reviews
This integrated approach strengthens submissions, accelerates timelines, and reduces pressure on internal teams. As a result, manufacturers can focus on additional projects, key milestones, and ongoing product development without compromising regulatory progress.
Supporting market access
Through close collaboration between MDx and manufacturers, companies can more effectively:
- Reduce regulatory risk, by ensuring requirements are met with robust and compliant evidence
- Accelerate conformity assessment through well-prepared documentation and proactive regulatory strategy
- Maintain long-term compliance across the product lifecycle, from initial submission to post-market activities
Key Takeaways: Placing Dental Medical Devices on the Market
Manufacturers that treat compliance as a strategic function (supported by the right expertise) are better positioned to place and maintain their products on the market without unnecessary delays or regulatory setbacks.
Regulatory compliance for dental products is:
- A lifecycle commitment, not a one-off project
- Heavily dependent on consistency and traceability
- Increasingly scrutinised under MDR
If you are preparing to bring a dental or medical device to market and require execution‑level MDx support, our team partners directly with manufacturers to provide comprehensive, end‑to‑end regulatory compliance services.
